Researchers in the "second study looked into the brain correlates of social decision-making in persons who suffer from MDD. It was observed that their brain activity during hazardous decision making (high vs. low) and choices of conduct (benevolence vs. deceit) were tracked using a 3T MRI scanner while they were participating in the modified trust game. The participants in this study were fifteen MDD sufferers and fifteen healthy controls. The behavior tendencies of both groups were very similar to those seen in research one. Researchers discovered that, as compared to those with a low chance of developing the disorder, MDD patients displayed hyper responsiveness in the insula, which is a brain region important in decision-making. When clinical participants were deceiving others, they showed reduced differentiated activity in the caudate nucleus and increased differentiated activity in the dorso lateral prefrontal cortex, respectively. Participants who were in good health, on the other hand, showed greater activity in the middle frontal lobe, which is involved in the interplay between risk and decision. These findings suggest that a sad mood has an impact on both the poor reward processing and the inflexible adaptation of actions to changing environmental situations. In MDD patients, these" neurological dysfunctions are responsible for their distorted social decision-making. Based on the observations that "MDD patients' social decision-making is affected both in terms of behavioral pattern and in terms of brain activity, it has been established that mood can influence social decision-making processes and that depression is related with increased risk. Because our findings provide neural evidence of social decision-making in MDD patients, they will shed light on the interaction between mood and social cognition. They will also help us gain a better understanding of possible mechanisms explaining the relationship between depressed moods and the social deficits that are present in people with MDD. This understanding will aid in the development of cost-effective treatments for persons suffering from emotional disorders in the future.